Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Nutriband Inc.NASDAQ: NTRB

Net Income · Q1 FY2026 · quarter ended Apr 2026

Net income declines year over year

Q1 FY2026 net income of $1.24M (cash outflow) fell 10.6% year over year, ahead of the -19.0% change in trailing-twelve-month net income. Sequentially, it rose 28.3% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Net income amounted to 404.1% of revenue in FY2025, down 85.8 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $18.28M (+322.1%) for the fiscal year ending Jan 2027, a step up from the -21.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-$1.24M+28.3% QoQ
Last fiscal yearJan 2026
-$8.23M-21.5% YoY
LTMApr 2026
-$8.08M-19.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.6%+100.0%+110.6 pp
1 year-21.5%+322.1%+343.6 pp
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(8.23M) USD
Year-over-year change
+21.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 net income of $8.08M is the smallest of the 9 companies compared; the peer median is $49.52M.
  • Its year-over-year change of -19.0% is the 7th highest of 8, against a peer median of -5.5%.
  • Net income amounts to 448.4% of revenue for NTRB, versus a peer median of 1360.6%.
NTRB Competitors Peer median
Net Income for NTRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.31M -5.5%+25.1%1360.6%
ACETAdicet Bio, Inc.LTM Mar 2026$108.83M -7.2%+18.7%—
FBIOFortress Biotech, Inc.LTM Mar 2026$102.15M +215.2%-46.4%154.4%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M -7.7%+35.7%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$58.88M -22.2%-28.5%—
XBITXBiotech Inc.LTM Mar 2026$40.16M +1.9%+11.4%—
ADAGAdagene Inc.LTM Jun 2024$31.85M —-39.6%3904.3%
GANXGain Therapeutics, Inc.LTM Mar 2026$21.24M +1.5%+4.7%—
NTRBNutriband Inc.LTM Apr 2026$8.08M -19.0%+22.4%448.4%
Peer median (excluding NTRB) $49.52M-5.5%+8.0%1360.6%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Net Income(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
Deferred Income Tax00000
Stock-Based Compensation897.83K732.13K742.7K1.54M104.4K
Change in Working Capital(541.38K)(219.32K)223.22K34.09K126.81K
Accounts Receivables42.97K(41.67K)(153.97K)74.8K(44.56K)
Inventory(78.8K)(97.69K)60.73K(43.44K)94.05K
Accounts Payables(145.26K)(104.86K)198.89K23.61K120.94K
Other Working Capital(360.29K)24.9K117.57K(20.89K)(43.63K)
Other Non-Cash Items2.23M614.51K704.17K3.99M2.67M
Operating Cash Flow(2.81M)(2.99M)(3.53M)(4.63M)(5.13M)
Capital Expenditures(81.6K)(79.3K)(51.76K)(92.04K)(5.32K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(81.6K)(79.3K)000
Investing Cash Flow(81.6K)(79.3K)(51.76K)(92.04K)(5.32K)
Debt Repayment(1.63M)(17.8K)2.09M8.69M(21.62K)
Common Stock Issued6.42M02.61M8.41M5.42M
Common Stock Repurchased(104.47K)(119.01K)0(149K)0
Dividends Paid(196.59K)0000
Other Financing Activities3.14M296.88K0690
Financing Cash Flow7.63M160.07K2.09M8.54M5.4M
Effect of Forex Changes00000
Net Change in Cash4.74M(2.91M)(1.49M)3.82M263.14K
Free Cash Flow(2.89M)(3.07M)(3.58M)(4.72M)(5.13M)

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.